Alkermes ALKS
NASDAQ ALKS
$45.31 -0.19 (-0.41%)
As of: Sep 9, 2026 · 2:09 PM EDT

Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022)

Alkermes' (ALKS) quarterly Non-Current Deffered Revenue came in at $6.4 million in Q3 2022, down 50.25% year-over-year from $12.9 million in Q3 2021, and down 44.3% quarter-over-quarter from $11.5 million in Q4 2021.

Analysis

Alkermes (ALKS) Non-Current Deffered Revenue (2011 - 2022) Analysis & Trends

Alkermes (ALKS) has reported Non-Current Deffered Revenue for 12 consecutive years, with $6.4 million the latest figure, recorded in Q3 2022.

  • On a quarterly basis, Non-Current Deffered Revenue fell 50.25% year-over-year to $6.4 million in Q3 2022; TTM through Sep 2022 was $6.4 million, a 50.25% decrease from a year earlier, with the FY2021 full-year figure at $11.5 million, down 29.92% from the prior year.
  • Non-Current Deffered Revenue was $6.4 million for Q3 2022 at Alkermes, down from $11.5 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $22.1 million in Q4 2019 and troughed at $5.0 million in Q3 2018.
  • A 5-year average of $12.8 million and a median of $11.6 million in 2019 frame the typical range for Non-Current Deffered Revenue.
  • Across the five-year window, Non-Current Deffered Revenue soared 131.69% in 2019 and plunged 50.25% in 2022, its largest moves.
  • Over 5 years, Non-Current Deffered Revenue stood at $9.5 million in 2018, then soared by 131.69% to $22.1 million in 2019, then retreated by 25.7% to $16.4 million in 2020, then decreased by 29.92% to $11.5 million in 2021, then tumbled by 44.3% to $6.4 million in 2022.
  • The last three Non-Current Deffered Revenue figures came in at $6.4 million (Q3 2022), $11.5 million (Q4 2021), and $12.9 million (Q3 2021), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 646.92 Bn 626.16 Bn 17.26 Bn -
2 AbbVie 441.93 Bn 435.36 Bn 12.70 Bn -
3 Merck 365.88 Bn 358.74 Bn 12.21 Bn -
4 Novartis Ag 266.57 Bn 258.88 Bn 11.24 Bn -
5 Pfizer 159.09 Bn 147.39 Bn 10.94 Bn -
6 Sanofi 52.44 Bn 45.05 Bn 10.79 Bn -
7 Revolution Medicines 44.05 Bn 44.05 Bn - -
8 Incyte 25.31 Bn 20.78 Bn 1.57 Bn -
9 United Therapeutics 21.45 Bn 18.78 Bn 683.80 Mn -
10 Alkermes 7.57 Bn 6.91 Bn 397.90 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 6.40 Mn
Dec 31, 2021 11.49 Mn
Sep 30, 2021 12.86 Mn
Jun 30, 2021 14.17 Mn
Mar 31, 2021 14.75 Mn
Dec 31, 2020 16.40 Mn
Sep 30, 2020 18.64 Mn
Jun 30, 2020 18.88 Mn
Mar 31, 2020 21.16 Mn
Dec 31, 2019 22.07 Mn
Sep 30, 2019 11.19 Mn
Jun 30, 2019 11.62 Mn
Mar 31, 2019 11.34 Mn
Dec 31, 2018 9.53 Mn
Sep 30, 2018 5.01 Mn
Jun 30, 2018 5.86 Mn
Mar 31, 2018 6.17 Mn
Dec 31, 2017 5.66 Mn
Sep 30, 2017 6.13 Mn
Jun 30, 2017 6.78 Mn